Glizid-M XR 60 Tablet is a combination oral hypoglycemic agent containing Gliclazide 60 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The extended-release formulation of Glizid-M XR 60 allows for sustained plasma drug levels, promoting better patient compliance through once-daily dosing and minimizing gastrointestinal side effects commonly associated with metformin. This combination therapy is particularly beneficial for patients inadequately controlled on diet and exercise alone or those who require dual mechanisms of action to achieve optimal glycemic targets. Glizid-M XR 60 should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with diabetic ketoacidosis, severe renal dysfunction, or known hypersensitivity to its components. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy to ensure safety and efficacy.